TWD
ADCT icon

True Wealth Design’s ADC Therapeutics ADCT Stock Holding History

True Wealth Design’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21
Closed -$79 – 2657
2026
Q1 		$79 Sell
21
-9
-30% -$35 ﹤0.01% 2506
2025
Q4 		$106 Buy
30
+9
+43% +$37 ﹤0.01% 2335
2025
Q3 		$84 Hold
21
– – ﹤0.01% 2483
2025
Q2 		$57 Sell
21
-72
-77% -$151 ﹤0.01% 2353
2025
Q1 		$132 Buy
+93
New +$158 ﹤0.01% 2106

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

True Wealth Design's ADCT Position: Q2 2026 in Review

True Wealth Design sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 21 shares — an estimated $79 sold.

True Wealth Design first reported a position in ADCT in Q1 2025 and held it in 5 quarters. The position peaked at $132 in Q1 2025. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • True Wealth Design reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • True Wealth Design sold 21 ADC Therapeutics shares in Q2 2026, an estimated $79.
  • True Wealth Design first reported a position in ADC Therapeutics in Q1 2025 and held it in 5 quarters.
  • True Wealth Design's ADC Therapeutics position peaked at $132 in Q1 2025.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.